SCHEMBL4195071

SCHEMBL4195071

O=C(Cc1ccc(F)cc1)c1c(O)c2cccnc2n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 5/20 0.44
THRB P10828 2/20 0.43
TP53 P04637 2/20 0.42
TRPV1 Q8NER1 1/20 0.42
POLB P06746 1/20 0.42
CNR1 P21554 1/20 0.41
PDE4B Q07343 1/20 0.40
PDE4D Q08499 1/20 0.40
MAPT P10636 3/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CXCR3 P49682 1/20 0.39
RGS4 P49798 1/20 0.39
RGS8 P57771 1/20 0.39
CCR1 P32246 1/20 0.38
PPARG P37231 1/20 0.38
LMNA P02545 1/20 0.38
TACR1 P25103 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4183644 0.94 TP53 (0.43) CNR2THRBTP53TRPV1POLB
SCHEMBL4187658 0.93 POLB (0.47) CNR2THRBTP53TRPV1POLB
SCHEMBL4183574 0.92 TP53 (0.44) THRBTP53TRPV1POLBPDE4B
SCHEMBL4189465 0.90 BCL2L1 (0.42) THRBTP53TRPV1POLBPDE4B
SCHEMBL4188348 0.88 CNR2 (0.43) CNR2TP53CNR1PDE4BPDE4D
SCHEMBL4185752 0.87 TP53 (0.47) TP53TRPV1POLBPDE4BPDE4D
SCHEMBL2408715 0.86 CNR2 (0.47) CNR2TP53CNR1PDE4BPDE4D
SCHEMBL4190734 0.85 PPARG (0.41) TP53TRPV1POLBPDE4BPDE4D
SCHEMBL4187079 0.85 PDE4B (0.41) TP53POLBPDE4BPDE4DMAPT
SCHEMBL13685422 0.85 TP53 (0.40) CNR2TP53TRPV1POLBCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A CNR2 2151/4885THRB 3052/4885TP53 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.